Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD4 | P21917 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95058 | 0.81 | PRCP (0.53) | ALDH1A1MAPTKDM4ETSHRPRCP | |
| SCHEMBL20577212 | 0.80 | CYP2D6 (0.38) | CHRNB2CHRNA4CYP2D6CYP3A4MEN1 | |
| SCHEMBL14395237 | 0.72 | CHRNB2 (0.44) | CHRNB2CHRNA4CYP2D6CYP3A4MEN1 | |
| SCHEMBL29568322 | 0.72 | CHRNB2 (0.44) | CHRNB2CHRNA4CYP2D6CYP3A4MEN1 | |
| SCHEMBL359802 | 0.72 | MAPK1 (0.42) | CHRNB2CHRNA4CYP2D6CYP3A4MEN1 | |
| SCHEMBL359803 | 0.72 | CHRNB2 (0.44) | CHRNB2CHRNA4CYP2D6CYP3A4MEN1 | |
| SCHEMBL5038527 | 0.72 | CHRNB2 (0.37) | CHRNB2CHRNA4CYP2D6CYP3A4MEN1 | |
| Hydrochloric Acid SCHEMBL27585427 | 0.71 | MAPT (0.44) | CHRNB2CHRNA4CYP2D6CYP3A4DRD1 | |
| Bromide SCHEMBL3966126 | 0.71 | CHRNB2 (0.42) | CHRNB2CHRNA4CYP2D6CYP3A4MEN1 | |
| SCHEMBL29035907 | 0.71 | CA1 (0.38) | CHRNB2CHRNA4CYP2D6CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560450-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2009-07-14 | — | — | US | claimed |
| US-20040138215-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-04 | — | — | US | disclosed |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-29 | — | — | US | disclosed |
| US-20210009572-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-14 | — | — | US | disclosed |
| US-10865200-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-15 | — | — | US | disclosed |
| EP-3134386-B1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-20 | — | — | EP | disclosed |
| US-10457670-B2 | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190241547-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20180346452-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-06 | — | — | US | disclosed |
| US-9868725-B2 | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-16 | — | — | US | disclosed |
| EP-0542525-B1 | Antithrombotic agents | LILLY CO ELI (US) | 1998-07-08 | — | — | EP | disclosed |
| EP-0837071-A1 | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1998-04-22 | — | — | EP | disclosed |
| EP-0685489-A2 | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0684258-A2 | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-11-29 | — | — | EP | disclosed |
| US-5430023-A | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-07-04 | — | — | US | disclosed |
| US-5416093-A | DIPEPTIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1995-05-16 | — | — | US | disclosed |
| US-5252566-A | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0542525-A2 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1993-05-19 | — | — | EP | disclosed |
| EP-0479489-A2 | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1992-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865200-B2 | Nitrogen-containing heterocyclic compound | CHRM1, CHRM5, CHRM2 | CHRNB2 21/4885CHRNA4 8/4885CYP2D6 2164/4885 |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | CHRNB2 21/4885CHRNA4 8/4885CYP2D6 2164/4885 |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | CHRNB2 21/4885CHRNA4 8/4885CYP2D6 2164/4885 |
| US-20180346452-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | CHRM1, CHRM2, CHRM5 | CHRNB2 22/4885CHRNA4 11/4885CYP2D6 802/4885 |
| US-20210009572-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRNA5 | CHRNB2 19/4885CHRNA4 8/4885CYP2D6 2373/4885 |
| US-20190241547-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | CHRNB2 21/4885CHRNA4 8/4885CYP2D6 2164/4885 |
| US-20040138215-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | CHRNB2 2519/4885CHRNA4 1566/4885CYP2D6 76/4885 |
| US-10457670-B2 | Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease | CHRM1, CHRM2, CHRM5 | CHRNB2 22/4885CHRNA4 11/4885CYP2D6 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.